

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Barnes-Jewish St. Peter's Hospital</p> <p>2. 10 Hospital Dr. Dept. of Radiology St. Peters, MO 63376</p>		<p>In accordance with letters dated September 18, 2025, and January 14, 2026,</p>	<p>4. Expiration Date: November 30, 2036</p>
		<p>3. License No.: 24-18968-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-17414 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Iodine-125 permitted by 10 CFR 35.400</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (IsoAID L.L.C., Model IAI-125A (Advantage I-125); Medi-Physics, Inc., d/b/a GE Healthcare, Model 6711 (OncoSeed); Theragenics Corporation, Model I-Seed AgX100)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 2 curies total</p> <p>D. 2 curies total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p> <p>D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.</p>

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-18968-01

Docket or Reference No.:
030-17414

Amendment No. 68

6. Byproduct, source, and/or special nuclear material

7. Chemical and/or physical form

8. Maximum amount that licensee may possess at any one time under this license

9. Authorized use

E. Palladium-103 permitted by 10 CFR 35.400

E. Sealed Sources (Theragenics Corporation TheraSeed, Model 200)

E. 2 curies total

E. For any manual brachytherapy procedure permitted by 10 CFR 35.400.



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-18968-01

Docket or Reference No.:
030-17414

Amendment No. 68

CONDITIONS

10. A. Licensed material shall be used or stored at the licensee's facilities located at Barnes-Jewish St. Peter's Hospital, 10 Hospital Dr. St. Peters, Missouri 63376.
- B. Licensed material listed in Item Nos. 6.D. and 6.E. shall also be used and stored at the licensee's facility located at Barnes-Jewish St. Peter's Hospital 100 Entrance Way, St. Peters, Missouri 63376.

11. The Radiation Safety Officer (RSO) for this license is Constance Courtois, M.D.

12. Licensed material shall only be used by, or under the supervision of:

- A. Individuals permitted to work as authorized users, in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)

Material and Use

Joelle Biernacki, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Constance Courtois, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Punita Gupta, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Lannis E. Hall, M.D.

10 CFR 35.300; 10 CFR 35.400

James Kelly, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Paula M. Leiva, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Hui Hua Shu, M.D.

10 CFR 35.100,10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-18968-01

Docket or Reference No.:
030-17414

Amendment No. 68

Authorized User (M.D., D.O., etc.)

Robert Stachecki, M.D.

Diana L. Westerfield, D. O.

Material and Use

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

10 CFR 35.200

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.
- A. Application dated June 21, 2021 (ML21173A131)
 - B. Letter dated July 15, 2021 (ML21201A246)
 - C. Letter dated August 19, 2021 (ML21238A247)
 - D. Letter dated October 19, 2021 (ML21307A432)
 - E. Letter dated August 9, 2022 (ML22250A463)
 - F. Letter dated September 18, 2025 (ML25345A014)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: January 30, 2026By: _____
Nathan Bryant
Region 3